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Introduction
Two prophylactic human papillomavirus (HPV) vaccines have 
the potential to prevent invasive cervical cancer and precancer-
ous disease attributable to oncogenic HPV types 16 and 18.1,2 
The quadrivalent vaccine can also prevent low-risk HPV types 6 
and 111 that cause genital warts. The US Advisory Committee on 
Immunization Practices recommends routine immunization of 
11  or 12 year-old females with either the bivalent HPV 16/18 or 
the quadrivalent HPV vaccine.3 How best to integrate these vac-
cines into existing medical, legal and health care policy structures 
to ensure the greatest public health benefit has been a topic of 
considerable debate.
School immunization requirements have been highly effective 
in increasing early childhood and adolescent vaccination rates 
in the US,4,5,6 and are currently recommended for both children 
and adolescents by the Task Force on Community Preventive 
Services.6 However, efforts to make HPV vaccination a require-
ment for girls to attend school have generated controversy, 
reportedly due to concerns over HPV vaccine safety, sexual trans-
mission of HPV infection, and vaccine requirements potentially 
violating civil liberties.7,8 As of December 2009, at least 24 states 
and the District of Columbia (DC) had introduced legislation 
to require HPV vaccination for adolescent girls before attending 
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school, with provisions allowing parents to opt out8-10; however, 
only Virginia and DC have enacted such regulatory laws.
Data are currently limited regarding attitudes toward school 
HPV immunization requirements among parents of girls within 
the target age group for HPV vaccination. Further, we know little 
about correlates of attitudes toward HPV vaccine requirements. 
We thus examined parental attitudes towards school require-
ments for HPV vaccination of female adolescents. 
Results
The median age of 866 parents surveyed was 43 y (range 21–79). 
Most respondents were female (94%) and reported educational 
attainment of college or greater (72%). Over half were white 
(54%), while approximately 40 percent were African American 
(43%). Respondents were evenly distributed among rural (47%) 
and urban (53%) residence (Table 1).
Overall, 46.4% of parents agreed that state-based laws requir-
ing HPV immunization for school attendance are a good idea 
(Table 2). In contrast, many more parents (83.6%) agreed that 
“these laws are okay only if parents can opt out if they want to.” 
In total, 43.9% of parents disagreed with the statement that 
state-based laws requiring HPV immunization for school atten-
dance are a good idea but agreed the laws are okay if parents 
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Factors associated with agreement with policies 
requiring HPV vaccination, when opt-out provi-
sions were not mentioned, appear in Tables 1 and 3. 
Parents’ socio-demographic characteristics, includ-
ing age, residence, education, race, marital status, 
reported income, and daughter’s age were not asso-
ciated with agreement with HPV vaccine school 
requirements (Table 1). Parents whose daughters had 
initiated HPV vaccine were more likely to agree with 
requirements requiring vaccination (OR = 5.0) as 
were those who intended HPV vaccination for their 
daughters within the next year (OR = 16.7).
Parents were less likely to agree with HPV vaccina-
tion requirements if they believed that the vaccine was 
unsafe (OR = 0.3) or caused lasting health problems 
(OR = 0.2)(Table 3). Some parents reported beliefs 
that HPV vaccination may increase their daugh-
ters’ sexual activity (19%), and those who did were 
less likely to approve of school entry requirements 
(OR = 0.4). Parents who believed HPV vaccine was 
being “pushed by drug companies” (OR = 0.3), or 
wanted to wait to decide whether to vaccinate their 
daughters (OR = 0.3) were also less likely to agree 
with HPV vaccination requirements.
Parents were more likely to agree with such require-
ments if they perceived more benefits from vaccination 
at earlier ages (OR = 16.1) or that HPV vaccine was 
effective in preventing cervical cancer (OR = 2.5) or 
genital warts (OR = 1.7). Parents were also more likely 
to agree with requirements for HPV vaccination if they 
anticipated greater regret if their daughters were not 
vaccinated and later acquired an HPV infection that 
could lead to cervical cancer (OR = 10.0).
Beliefs that the decision to give HPV vaccines 
should be the parents’ alone (OR = 0.3) and that the 
vaccine was too new for school requirements (OR = 
0.3) were associated with less agreement with HPV 
vaccination requirements. Parents who believed that 
all girls and all boys should get HPV vaccine were 
more likely to agree with HPV vaccination require-
ments (OR = 33.3; OR = 7.9, respectively).
Discussion
Many US states have considered policies that require 
HPV vaccination prior to entry into middle school.10 
Of parents surveyed, approximately half thought 
such requirements are a good idea. However, the vast 
majority, over 80%, agreed with school entry require-
ments when they included opt-out provisions. Parents 
supportive of requirements had favorable opinions of 
HPV vaccine safety and efficacy, believed that the 
vaccine offered more benefits if their daughters were vaccinated 
sooner, or had vaccinated or intended to vaccinate their daughters 
against HPV. Parents less supportive of vaccination requirements 
Table 1. Socio-demographic characteristics and daughter’s vaccination status associ-
ated with support for laws requiring HpV vaccination for school attendance
 School requirements for HPV vaccination 
“are a good idea”
Total (N=866) Agree
n %† % OR (95%CI)
Socio- Demographic characteristics
Parent’s age, years 
<40 241 49.2 46.2 1
40-44 326 26.5 47.2 1.0 (0.7–1.7)
>45 306 24.2 45.9 1.0 (0.6–1.7)
Parent’s residence
Rural 428 47.3 42.3 1
Urban 438 52.7 50.1 1.4 (0.9–2.0)
Parent’s race
White 607 52.0 43.4 1
Black 204 38.1 51.5 1.4 (0.9–2.1)
Other 55  9.9 42.6 1.0 (0.4–2.2)
Parent’s education
<High school 187 28.3 46.7 1
>Some college 679 71.7 46.3 1.0 (0.6–1.7)
Parent’s marital status
Married or living together 730 83.3 46.3 1
Divorced 59  6.2 50.8 1.3 (0.5–2.5)
Single or never married 39 10.4 47.5 1.1 (0.4–2.5)
Parent’s annual household income 
(US dollars)
<50,000 321 46.6 46.4 1
≥50,000 545 53.3 46.4 1.0 (0.7–1.4)
Daughter’s age, years
>16 332 32.5 49.4 1
13-16 378 45.4 48.1 0.91 (0.6–1.4)
9-12 156 22.0 38.3 0.63 (0.3–1.1)
 Vaccination initiation by daughter
Daughter has had ≥1 dose of HpV 
vaccine
No 761 89.6  43.1 1
Yes 105 10.4  75.0 5.0 (2.0–10.0)*
Will get daughter HPV vaccine in 
the next year†
Definitely or probably will not 258 32.4 9.4 1
Definitely or probably will 465 62.0 61.8 16.7 (10.0–25.0)*
Do not know/ Refused 38  5.7 30.5 5.0 (1.4–10.0)*
proportions, odd ratios and confidence intervals are weighted. Odd ratios (OR) and 95% 
confidence intervals (cI) adjusted for parent’s age, daughter’s age and residence.  
*p < .05; †among caregivers whose daughter has not been vaccinated
can opt out. Only 9.7% did not agree with either statement, and 
opposed school HPV vaccine requirements regardless of opt-out 
provisions.
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to required school-entry provision of HPV vaccine among par-
ents of female adolescents eligible for HPV vaccine. Additional 
study strengths include a large sample size and a focus on women 
living in rural counties with elevated cervical cancer rates. Study 
limitations include the collection of data from one geographical 
area of North Carolina, and thus the generalizability to other 
regions of the US will need to be established. Although most 
households in the US have telephones,21 a selection bias could 
potentially exist since all participants were contacted by phone. 
Our results are also based on parents’ attitudes toward hypotheti-
cal HPV vaccination requirements for school entry, rather than 
actual policies.
Our findings suggest that public support for HPV vaccine 
school immunization requirements will depend on education of 
parents about HPV vaccine safety and efficacy, as well as the ben-
efits of vaccination at the recommended age range. If proposed 
requirements contain opt-out provisions, public education about 
these provisions is also likely to increase acceptability, given 
our finding that the vast majority of parents of adolescent girls 
favored requirements with opt-out provisions. For other vaccines 
state mandates do allow some exemptions. In addition to medical 
exemptions for required vaccination allowed by all 50 states,22 48 
states allow religious exemptions, and 18 states permit exemp-
tions for “philosophical reasons.”22 For HPV vaccination require-
ments, all currently proposed state regulations offer provisions 
allowing parents to “opt out” of giving their daughters HPV vac-
cine,10,23 although opt-out provisions differ by state.7,24,25 In the 
two jurisdictions where laws on requirements for HPV vaccina-
tion have already been enacted, Washington DC and the state of 
Virginia, parents can opt out for any reason.10 States will also have 
to weigh the potential downside of opt-out provisions, given that 
in geographical areas with broader exemptions for other required 
vaccines, decreased vaccine uptake and an increased incidence 
of vaccine-preventable disease has been observed, as compared 
with areas without such exemptions.23,26,27 States that pass school 
requirements will also need to ensure that the necessary financial 
support and logistical systems are in place for vaccine delivery to 
adolescents.28
Requiring HPV vaccination for school entry is one strategy 
to increase immunization coverage among adolescents, which 
may also potentially decrease existing cervical cancer health dis-
parities.29 However, outside the US, other strategies that do not 
involve school-entry requirements have been effective. Countries 
such as Australia, Canada, and the UK have achieved notably 
high rates of HPV vaccine coverage among female adolescents 
Table 2. agreement with school requirements for HpV caccine among 866 parents of female adolescents in North 
carolina
“Some states are trying to pass laws that would 
require all 11 and 12 year-old girls to get the HpV 
vaccine before they are allowed to start 6th grade.”
“I think these laws are a good idea.”
“Okay to have these laws only 
if parents can opt-out.”
agree, n (%) Disagree, n (%) Total, n (%)
agree 330 (39.7) 382 (43.9) 712  (83.6)
Disagree 58  (6.7) 96  (9.7) 154  (16.4)
Total 388 (46.4) 478 (53.6) 866 (100.0)
Note: all percentages shown are out of the total sample and are weighted.
reported more concerns related to HPV vaccine safety, its promo-
tion by drug companies, its relatively short time on the market, and 
potential for the vaccine to increase their daughters’ sexual activity.
Parents who believed HPV vaccine had been on the market 
for too short a time were more likely to be opposed to school 
HPV vaccination requirements. Efforts to enact requirements for 
HPV vaccine have differed from other vaccines, in that there was 
relatively little time between recommendations for HPV vaccine 
by advisory committees and when legislators proposed school 
entry requirements.11 Thus, public knowledge about HPV vac-
cine, experience with HPV vaccine implementation, and data on 
vaccine safety were relatively limited at that time. This is impor-
tant because parents who reported greater concerns about HPV 
vaccine safety and longer term health problems were more likely 
to be opposed to school requirements. Monitoring of HPV vac-
cine safety is currently ongoing through both passive and active 
systems.12-14 As of June 2011, more than 35 million doses of the 
quadrivalent HPV vaccine had been distributed in the US, and 
careful analysis of reports to the passive Vaccine Adverse Events 
Reporting System (VAERS) during this time frame did not find 
a common pattern to reports that would suggest that serious 
adverse events were caused by HPV vaccine.12,13
Differences between HPV infection and other vaccine pre-
ventable diseases may contribute to resistance to school require-
ments.9 HPV vaccines are primarily intended to prevent a genital 
cancer caused by a sexually transmitted virus. Requirements 
have been made for other adolescent vaccines in many states.15 
However, most other requirements for school entry have been 
for vaccines to prevent infections that are highly transmissible 
through casual contact,16 although there are exceptions such as 
tetanus.7 Nonetheless, while concerns have been expressed about 
required HPV vaccination due to its prevention of a sexually 
transmitted infection,17 school immunization requirements have 
previously been implemented for hepatitis B17,18 which is primar-
ily transmitted sexually in the US.
Beliefs that HPV vaccination may result in a girl being more 
likely to have sex, while endorsed by less than 1 in 5 parents, 
were more common among parents who disagreed with school 
requirements. Some opponents of HPV vaccine have suggested 
that the administration of the vaccine to middle school girls 
could encourage sexual promiscuity.19 However, studies have not 
found that vaccination against other infectious agents increases 
behavioral disinhibition or risky behaviors.20
The present study, to our knowledge, is among the first to 
examine specific factors associated with support of or opposition 
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Table 3. parental attitudes associated with support for laws requiring HpV vaccination for school attendance
 School requirements for HPV vaccination  
are a good idea
Total (N=866) Agree
N %† % OR (95%CI)
Attitudes toward HPV vaccine
HPV vaccine is unsafe
Disagree 530 61.1 56.3 1
agree 101 12.7 24.7 0.3 (0.1-0.5)*
Do not know/ Refused 235 26.2 33.7 0.4 (0.2-0.6)*
HPV vaccine causes lasting health problems
Disagree 333 37.2 62.5 1
agree 214 27.2 28.8 0.2 (0.1-0.4)*
Do not know/ Refused 319 35.5 42.9 0.5 (0.3-0.8)*
If a teenage girl gets HPV vaccine, she will be more likely to have sex
Disagree 654 77.0 51.5 1
agree 170 18.7 29.6 0.4 (0.2-0.6)*
Do not know/ Refused 42 4.2 28.4 0.3 (0.2-0.8)*
HPV vaccine is being pushed by drug companies
Disagree 446 52.7 58.4 1
agree 289 30.0 30.2 0.3 (0.2-0.5) *
Do not know/ Refused 131 17.3 38.0 0.4 (0.2-0.8) *
HPV vaccine is so new, want to wait a while before deciding to get 
daughter vaccinated†
Disagree 221 30.0 61.7 1
agree 522 67.5 32.8 0.3 (0.2-0.6) *
Do not know/ Refused 18 2.4 71.8 1.7 (0.4-5.0)
More benefit if daughter gets HPV vaccine sooner†
Disagree 158 19.4 7.4 1
agree 512 68.8 54.9 16.1 (8.4-31.0)*
Do not know/ Refused 91 11.7 33.1 6.5 (2.6-16.4)*
Perceived HPV vaccine effectiveness against cervical cancer
Slightly/ Moderately 286 35.0 37.0 1
Very/ extremely 359 40.0 62.6 2.5 (1.7-5.0) *
Do not know/ Refused 221 25.0 33.7 0.9 (0.5-1.4)
Perceived HPV vaccine effectiveness against genital warts
Slightly/ Moderately 308 40.2 45.1  1
Very/ extremely 245   26.0 57.4 1.7 (1.0-2.5) *
Do not know/ Refused 313 33.9 39.5 0.8 (0.5-1.3)
Anticipated regret if daughter not vaccinated and later acquired 
type of HPV that can lead to cervical cancer†
Not at all/ a little/ 87 11.6 6.7  1
Moderate/ a lot 653 86.2 48.5 10.0 (5.0-50.0) *
Do not know/ Refused 21 2.2 22.3 5.0 (0.9-25.0)
Attitudes toward HPV vaccine requirements
Decision to give HPV vaccine should be parents' alone
Disagree (includes do not know/ refused) 195 20.8 70.5 1
agree 671 79.2 40.0 0.3 (0.2-0.5) *
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through school-based delivery programs that provide HPV 
vaccine free of charge, without school-entry requirements.30,31 
Australia successfully implemented a school-based approach and 
achieved uptake rates for the 3-dose HPV vaccine series on the 
order of 70–80% within the first year.32 In the US, HPV vaccina-
tion initiation rates among female adolescents aged 13–17 were 
44% in 2009, with only a little over one quarter (27%) complet-
ing the three doses series.33 Further examination of the feasibility 
and impact of school-based immunization programs in the US is 
needed. Over the next few years, data will likely be available from 
states that have adopted school HPV immunization requirements 
with opt-out provisions as well as from pilot school-based immu-
nization programs.34 Information from all of these efforts may 
provide important insights about optimal approaches to increase 
HPV vaccine coverage in the US, thereby reducing the burden of 
cervical cancer and other HPV-related diseases.
Methods
Caregivers (i.e., parents or guardians) of adolescent girls aged 
10–18 y were interviewed between July and October 2007 as 
part of the Carolina HPV Immunization Measurement and 
Evaluation (CHIME) Project in five southeastern North Carolina 
counties with elevated rates of invasive cervical cancer, as previ-
ously described.35 In brief, nine counties clustered in southeastern 
North Carolina met study inclusion criteria (higher than average 
cervical cancer rates and ⩾ 20% African-American residents). 
After matching eligible counties on population size, proportion 
of African American residents, and cervical cancer rates, we ran-
domly selected four rural counties to study (Duplin, Harnett, 
Sampson, and Wayne counties), and chose the one urban county 
(Cumberland) in this region. The vast majority of caregivers 
interviewed (97%) reported being the parent of the index child, 
and thus we refer to participants as parents. Parents were selected 
using a dual-frame, probability sample. Most participants (95%) 
came from a targeted-list frame consisting of directory-listed 
residential telephone numbers with available demographic infor-
mation, while the remainder of the sample (5%) came from a 
non-overlapping, list-assisted random digit dialing telephone 
frame. Rural residence was based on US Census classification 
for the census block where the respondent was living.36 Trained 
interviewers attempted to interview the primary female care-
giver; if she was not available, they interviewed the next available 
caregiver. Of 1,220 eligible parents, 889 (73%) parents partici-
pated.35 The University of North Carolina institutional review 
board approved the study protocol.
The telephone survey included questions on attitudes toward 
school HPV vaccination requirements, respondents’ socio-demo-
graphic characteristics, parents’ beliefs about HPV vaccines, 
HPV vaccine initiation by daughters, and intentions to have 
daughters vaccinated. Questions on attitudes were selected based 
on a systematic review of the literature on HPV vaccine accept-
ability in the US.37 Potential predictors of agreement with HPV 
vaccine requirements included health belief model constructs 
(beliefs about likelihood and severity of cervical cancer; beliefs 
about HPV vaccine benefits, safety, and perceived barriers; and 
doctor’s recommendation), as well as demographic characteristics 
of parents and their daughters.38 After stating that “some states 
are trying to pass laws that would require all 11 and 12 year-
old girls to get the HPV vaccine before they are allowed to start 
6th grade,” interviewers asked whether parents agreed with the 
statement, “I think these laws are a good idea.” We dichotomized 
responses as being in agreement (somewhat and strongly agree) 
or opposition (somewhat and strongly disagree). Parents were 
then asked whether they agreed with the statement: “It is okay 
to have these laws only if parents can opt out if they want to.” 
Analyses excluded data for parents who answered “don’t know” 
to either question (n = 23).
Table 3. parental attitudes associated with Support for Laws Requiring HpV Vaccination for School attendance (continued)
 School requirements for HPV vaccination  
are a good idea
Total (N=866) Agree
N %† % OR (95%CI)
HPV vaccine is too new for laws like these
Disagree 197 24.1 67.2 1
agree 660 72.9 38.6 0.3 (0.2-0.6) *
Do not know/ Refused 9 3.0 68.8 1.1 (0.1-10.0)
All girls should get HPV vaccine
Disagree 227 25.3 4.6 1
agree 574 65.3 62.4 33.3 (16.7-100.0) *
Do not know/ refused 65 10.8 49.1 20.0 (5.0-50.0) *
All boys should get HPV vaccine
Disagree 198 25.1 15.8 1
agree 564 63.9 58.3 7.9 (3.6-17.4)*
Do not know/ refused 104 11.0 47.8 5.2 (2.0-13.5)*
Note: proportions, odd ratios, and confidence intervals are weighted. Odds ratios (OR) and 95% confidence intervals (cI) adjust-
ed for parent’s age, daughter’s age, and residence. *p < .05; †among caregivers whose daughters had not been vaccinated. 
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We assessed predictors of positive parental attitudes toward 
HPV vaccine school requirements, by evaluating which fac-
tors were associated with agreement with the general statement, 
“These laws are a good idea,” when opt-out provisions were not 
mentioned. We calculated odds ratios (ORs) and corresponding 
95% confidence intervals (CIs) using logistic regression mod-
els that adjusted for socio-demographic factors that could be 
associated with parents’ attitudes toward vaccination, including 
parent’s age, daughter’s age, and rural vs. urban residence. We 
applied sampling weights to analyses to account for the study 
design and adjust the sample to reflect the county populations 
using 2000 US census data39 Statistical tests were two tailed, 
with a critical α of 0.05. Data were analyzed in SAS 9.1 (SAS 
Institute Inc., Cary, NC).
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